Skip to content

Clinical trials

Observational Seizures trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Seizures Phase: Observational Clear all

199 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20022
20033
20042
20055
20066
20073
20083
20094
20105
20118
20125
20139
20147
20156
201615
201712
201814
20198
202012
202110
20228
202312
20249
202512
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed105
Recruiting33
Unknown status28
Terminated12
Active, not recruiting10
Withdrawn5
Not yet recruiting4
Enrolling by invitation2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Neurological Disorders and Stroke (NINDS)21
Assiut University4
Aziende Chimiche Riunite Angelini Francesco S.p.A4
Brain Sentinel4
Eisai Co., Ltd.4
Children's Hospital of Fudan University3
National Institute of Allergy and Infectious Diseases (NIAID)3
UCB Pharma3
AstraZeneca2
Balikesir University2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Seizures199
Epilepsy105
Epilepsies, Partial9
Status Epilepticus9
Intellectual Disability7
Brain Injuries, Traumatic6
Cerebral Hemorrhage6
Epilepsy, Absence5
Nervous System Diseases5
Stroke5

Trials

Showing 76 to 100 of 199. Each trial links to its page on Pharma Observatory.

99 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.